Harry Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Richard L. Cassin Editor at Large

Elizabeth K. Spahn Editor Emeritus 

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor

FCPA Blog Daily News

« Learning curves are chances to do things better | Main | The FCPA versus global terrorism »

Spanish pharma wins DOJ declination

In an SEC filing this week, Spanish pharmaceutical firm Grifols SA said the DOJ issued an 'official declination to all inquiries related to the possible violation of the Foreign Corrupt Practices Act (FCPA) that were underway since July 2009.'

It said the investigation related to Talecris, acquired by Grifols in 2011.

'These investigations started prior to the acquisition of Talecris by Grifols,' the company said, 'and correspond to actions carried out when Talecris was part of the Bayer Group.'

Grifols said it has been cooperating with the DOJ by reporting all internal findings about potential FCPA violations.

As reported this week by the Wall Street Journal, an internal investigation at Talecris examined sales in Belarus, Russia, Iran, Brazil, Bulgaria, China, Georgia, Libya, Poland, Turkey, and Ukraine. Talecris had notified the DOJ in 2009 of the investigation and 'suspended operations in several countries while adding safeguards against foreign bribery, in some cases terminating consultants and distributors,' the Wall Street Journal said.

Grifols said in issuing the declination, the DOJ mentioned 'the significant cooperation of Grifols . . . to secure valuable information and making responsible decisions that [led] to the early disclosure of information to the DOJ.'

The company also said it took remedial action and strengthened its compliance program.

Grifols SA's full FCPA disclosure in its Form 6-K (Report of Foreign Issuer) is here.

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
All HTML will be escaped. Hyperlinks will be created for URLs automatically.